Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer
Breast cancer tumors with specific immune cell types fare better regardless of treatment, and immune cell presence alone doesn't guarantee response—pinpointing what truly matters.
This J Immunother Cancer study uses single-cell spatial transcriptomics of 212 TNBC tumors validated in 4 independent cohorts to identify pDCs and IFN-α/γ responses as hallmarks of effective anti-tumor immunity and improved outcomes across therapy types. Critically, immune-excluded tumors show poor outcomes despite high stromal TILs, demonstrating that sTIL scoring alone is insufficient for prognosis in TNBC.
What the study was
- Study design
- Multi-cohort spatial transcriptomics with validation in 4 independent datasets
- Population
- TNBC patients (discovery n=212, validation: FinXX, CALGB-40603, I-SPY 2, RWCGD)
- Sample size
- 212
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- J Immunother Cancer
Why it surfaced
Multi-cohort validation (4 independent datasets) with spatial single-cell methods. pDC/IFN findings are actionable: challenge current sTIL-only prognostication and point toward immune-excluded TNBC as a high-priority target. Mayo Clinic/Vanderbilt provenance. Score 7 — close to HIGH.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.